← Oncology Approval Tracker

FDA DECISION ·

Welireg + Keytruda / Keytruda Qlex

belzutifan with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph · Merck

FDA approvalNew or expanded indicationRenal cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adjuvant treatment for adults with clear-cell component renal cell carcinoma at intermediate-high or high risk of recurrence after nephrectomy, with resection of metastatic lesions where applicable.

LAMPGEN ANALYSIS

Why it matters

The HIF-2α inhibitor enters a postsurgical setting with pembrolizumab. Recurrence risk and disease-free survival matter when weighing a combination for patients with no evidence of disease after surgery.

What research teams should watch

Verify pathology, surgery date and risk classification. Track recurrence and distinguish treatment-emergent effects from postsurgical symptoms.

PRIMARY RECORDS

Sources